BioSpace News Archive

Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today announced that it will present two new posters at the American Association for Cancer Research Virtual Annual Meeting

Paul Brennan, NervGen’s President & CEO, stated, “We made substantial progress in the development of our lead program, NVG-291, towards clinical trials during 2020.

Axiom Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at the annual Outsourcing in Clinical Trials Israel on April 12th, 2021

Throughout Canada, communities and families continue to grapple with the ongoing overdose crisis and other harms associated with problematic substance use.

Recently, a patient with a broken wrist presented to a location of OrthoNOW®, a walk-in orthopedic center for emergencies, pain assessment/treatment and rehabilitation.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today presented the medicinal chemistry strategy for FTX-6058 at the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2021 National Meeting.

Rapid Dx Laboratory has partnered with Concentric by Ginkgo to support America’s K-12 schools by offering RT-PCR COVID-19 testing in Houston.

Repertoire Immune Medicines , a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, today announced the presentation of translational data obtained from applying its proprietary antigen-specific TCR-MHC DECODE™ platform in its Phase 1 trial evaluating PRIME IL-15 (RPTR-147)

Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to make efficacy labeling change with clinical data.

Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscience Company thanks Director Robert W. Pangia as he retires from the Board